[18F]-FEPPA...............T74

mPFC...............M48, M193

1000 Genomes Project...............T213

1H MRS...............16.3, M195, M214, T40, T131, W163

22q11...............T208

22q11 mitochondria...............10.4

22q11.2 CNV...............T92

2-Deoxyglucose...............W164

31P Magnetic Resonance Spectroscopy...............4.2, W184

3-hydroxykynurenine...............M161

5CSRTT...............M141

5HT2...............M218

5-HT2A receptor...............49, 49.2, W239

7-Tesla...............W205

A

ABIDE................T150

Accumbens................3.3, M48, M193

ACE................M137

Acetaminophen................T96

Acetylcholine................T64, T69

Acoustic Startle................M192

Actigraphy................M71

Actin Remodeling................M241

Activated Microglia................W3

Acute and Chronic Stress................7.1, 26, 26.2, M53, M211, T149, W11, W60, W85

Acute Stress................M2, M213, T49, T72, T218, T257, W9

Adaptive Behavior................W9, W69

Adaptive Immunity................T142

Adaptive Testing................32.2

Addiction................29, 29.4, 36, 36.2, 36.4, 39, 40.2, 44, 44.2, 44.4, 46.3, 52, 52.1, 57.3, M139, M164, M222, M237, M242, M251, T46, T241, T256, T261, W233, W240, W250, W264, W265

Adhesion Molecules................31.2

Adiponectin................M31

Adipose Tissue................T121, W147

Adjunctive Treatment................W118

Adoelscent Academic Performance................T265

Adolescence................8, 8.2, 13.3, 13.4, 23.1, 29, 29.2, 29.3, M17, M26, M59, M97, M106, M188, M226, M266, T12, T13, T60, T202, W24, W40, W215, W224, W241

Adolescent Alcohol................9.1, M34, M46, M258, T196, W22

Adolescent Alcohol Exposure................W223

Adolescent Depression................1.3, 42.1, M107, T89, W36, W52, W59

Adolescent Development................13, M79, W213

Adolescents................8.1, 8.3, M110, M228, M236

Adrenergic Receptor................2.1

Adult Anxiety................9.1

Adult Hippocampal Neurogenesis................M75, T37, T92

Adverse Childhood Events................T137, W5

Adversit................y42

Affective Disorders................15, 40

Affective Neuroscience................M94

Age Effects................33.3, M22, W53, W55

Aggression................30, 30.1,30.2, 30.4, 40.3, T16, W84

Aging................M3, T64, T139, W183

Aging And Dementia................17.3, M4, M37, T63

Agitation................M246

Ahhedonia................41

AKT1/ AKT3................W132

Alcohol................6.1, 40.2, 46, 46.1, M222, M239, M249, T256, T264, W133, W224, W226, W229

Alcohol Abuse................T196

Alcohol and Substance Use Disorders................W233

Alcohol Consumption................46.4, M233, W261

Alcohol Dependence................40.2, 40.4, 44.2, 44.4, M125, M262, T221, T230, T237, T245, T263, W236, W255

Alcohol Exposure................W140

Alcohol Intake................T228, T231

Alcohol Preferring P Rats................W225

Alcohol Relapse Treatment................44.3

Alcohol Self-Administration................44.3, M233, T230, T255

Alcohol Use................T265

Alcohol Use Disorders (AUD)................11.2, 40, 40.1, M202, M224, M233, M249, T54, T236, T254, W235

Alcohol Withdrawal................46.2

Alcoholism................M264

Alcohol-Seeking Behavior................M242, M254

Allelic Bias Analysis in RNASeq................M267

Allometry................M27

Allopregnanolone................M76

Alpha 1A, Alpha 1B, 5-Ht1A, And 5-Ht2A Receptors................T132

Alternative Splicing................T35, T177

Altitude................M72

Alzheimer's Disease................M36, M37, M177, T95, W135

AMPA Glutamate Receptors................13.2, 14.1, 33, 43.4, W106

AMPA Receptors................M184, T207, W78, W238

Amphetamine................52.3, M135, M234, T147, T229, W182

Amygdala................7, 9.1, 18.4, 42.3, 46.1, M143, T2, T9, T10, T14, T22, T60, T70, T71, T75, T77, T81, W7, W61, W98, W255

Amygdala-Based Networks................13.1, M107, T258

Amyloid................T63, W37

Amyloid Precursor Protein................W130

Anandamide................M226, W199

Anesthetic................W95

Anhedonia................1.1, 15.2, 26.1, 41.2, M200, T89, W52, W72, W115, W237

Animal Models................12.4, 24.4, 40.3, 51.3, 58.3, 59.4, M95, M102, M118, M227, T24, T118, T181, T200, W90, W258, W264

Ankryin-G................W90

Ankyrin................W148

Anorexia Nervosa................54.4, M40, W23, W41, W42, W43, W146

Antemortem................M38

Anterior Cingulate Cortex................16.2, M28, M55, M141, T40, T144, T170, T268, W116

Anterior Prefrontal Cortex................T4

Anthranilic Acid................M161

Antibody................T155

Anti-Brain Antibodies................47.4

Antidepressant Agents................M118, W73, W102

Antidepressant Response................M99, T20, T137

Antidepressant Treatment Practice................M85, M93

Antidepressant Trials................5.4

Antidepressant................s5, 56.2, M78, M124, T121, W60, W88, W95, W101

Antimicrobials................47.2

Antipsychotic Agents................T24

Antipsychotic Induced Weight Gain................M31, T84

Antipsychotic Medication................T189, W185, W210

Antipsychotic Treatment................M151, W180

Antipsychotic-Associated Obesity................T186

Antipsychotic-Naïve First-Episode Schizophrenia................59.1, M179, T166, W199

Antipsychotics................49.2, 55.4, M86, M163, M168, M169, M173, M176, M177, M180, M181, T179, T181, T186, W173, W194

Antisocial Personality Disorder................30.1, M160

Anxiety................1.2, 1.3, 5.1, 12, 24, 24.1, 26, 31, 31.2, 31.3, 39.4, 40.3, 54, 54.2, 54.4, M13, M17, M63, M75, M106, M108, M171, T1, T2, T5, T9, T27, T49, T54, T63, T70, T76, W11, W19, W98, W100, W104, W124

Anxiety Circuitry................T6, T77, W70

Anxiety Disorder................s11, M16, M122, W48

Anxiety State................T65

Anxious Depression................T33

Apathy................T157, W120, W157

APD-Induced Metabolic Disease................1.4

Apo................E55.2, M36

Apoer................255.2

Apoptosis................M258, T130

Appetite................W65, W82

Approach-Avoidance................W112

Arc................T34, T46

Aripiprazole................T246

Aripiprazole Once-MonthlyT116

Artificial Intelligence................W127

Artificial Learning................T265

AS3M................T20.4

ASCT-2 transporter................56.2

Aspirin................W160

Assessment................32.2

Associative-Striatum................T192

Astrocytes................22.3, 29, 29.3, 43, 43.1, 43.2, 43.3, 43.4, T244, W207

ATAC-seq................W172

At-Risk................T245, W64, W110

Attention................26.1, M141, T69, W64, W139

Attention Deficit Hyperactivity Disorder (ADHD)................30, 30.1, 30.4, M24, M29, M47, M221, M252, T17, T82, T102, T147, T266, W48, W49, W124, W129, W245

Attentional Bias................M243

Atypical Antipsychotic Drug................W105

Atypical Antipsychotics................1.4, M93, T211, T246, W63, W114

Audition................M208

Auditory................W189

Auditory Cortex................M214, T36

Auditory Deficits In Schizophrenia................M201, W170

Auditory Hallucinations................M186, M194, M206, W178

Auditory Short-Term Memory................M201

Autism................22.4, 51, 51.3, 58, 59, 59.4, M25, M146, M156, M158, M192, T80, T82, T150, T153, W33

Autism & Depression................48.1

Autism Spectrum Disorders (ASD)................2.2, 22, 22.1, 50.2, M22, M23, M30, M153, T35, T85, T87, T97, W25, W27, W31, W32, W143, W148, W156

Autoimmune Encephalitis................47

Automated Computational Language Speech Faces................W191

Automated Memory-Screening Test................T94

Autopsy Brains................W176

Avoidance................3.3

Axon Guidance Molecule Genes................T154, W153

Axonal Transport................T172

Axons................W185

Aβ42................W135

B

Baby Schema................W243

Baby-Cry................M108

Baclofen................T264

Bariatric Surgery................W137

Basal Ganglia................10.2, 46.3, 54.2, M164, T148

Basolateral Amygdala................13.2, M9, M20, W225

Bath Salts................W256

Bayesian Inference................M194

BDNF................M82, M97, M155, M223, T83, T251, W102, W113, W121

BDNF Delivery................W150

Bed Nucleus Of The Stria Terminalis................12.4, 26.2, T77, T230, W19, W122

Behavior................53, 53.2, 56.1, T106, T141, T176, W33, W233

Behavioral Analysis................W209

Behavioral Despair................1.1

Behavioral Flexibility................T263

Behavioral Inhibition................T198

Behavioral Pharmacology................T20, T48, T95, T232, T266

Bench-To-Bedside................44

Beta Arrestin................T148

Beta-Amyloid Peptide 1-42................M36

Big Five Personality Factors................M67, W158

Binge Drinking................M249, T223, W221

Binge Eating................T98, T100, T102

Binge Eating Disorder................T101

Biobanks50.4

Biobehavioral Effects................T264

Biochemistry................W209

Bioenergetics................W184

Bioinformatics................M26

Biological Marker................W204

Biomarkers................4.1, 5.4, 6, 6.1, 6.2, 21.2, 23.2, 32, 38, 47.1, M4, M30, M83, M85, M91, M105, M204, T85, T87, T137, T245, W10, W51, W88, W135, W182

Biotype................W204

Bipolar................M199, M207

Bipolar Depression................T31

Bipolar Disorder................1.2, 23.1, 36.1, 38.3, 50, 50.3, M79, M81, M90, M94, M106, M109, M110, M116, M125, T30, T62, T130, T133, T160, T162, T190, T193, T200, T209, T217, W57, W58, W64, W80, W90, W105, W110, W114, W162, W212

Bipolar I Disorder................T116

Blood................M87, W2

Blood-Brain Barrier................44.1, 47.3, 47.4, T29

Body Weight................T121

BOLD imaging................T4, W75, W110, W154, W243

Borderline Personality Disorder................M160, T158, T159

Brain................20, 50.3, M27, M87, W67, W69

Brain Based Markers for Depression................17.2, 21.4

Brain Development................7.1, 8, 13.4, 22, 42, 61.1, M21, T14, W172

Brain Imaging................37, M108, W167, W203

Brain Initiative................37

Brain pH................T200

Brain Stimulation................17.1, 17.3, M206, M222, W15

Brain Structure................W220

Brain Tissue................W175

Brain Transcription................20.4

Brain-Derived Neurotrophic Factor................W73

Brexpiprazole................T171, T199, W118

Brodmann are................a25, M74

Bulimia Nervosa................61.2, M42, T15, W40, W44

Buprenorphine................T49, T114

Buprenorphine-Naloxone................M231

Bupropion................M85, W260

C

C_ SSRS................W128

CA3 Metaplasticity................2.4

Cachexia................W146

CACNA1C................M109

Caffeine................W256

Calcium................2.1, 43.1, W200

Calcium Imaging................24.2, M58, M109, T55, T233, W47, W70, W222

California Verbal Learning Test................T133

Callosotomy................W149

CAM................T152

Camk2a................T209

Camp Signalling................W102

Cancer................T152

Cannabidiol................M245, T220, W202

Cannabinoid Receptor................8.4, W158

Cannabinoids................29.4, 46.3, T250, W258

Cannabis................29.1, 29.4, 57.2, M246, T267, W227, W242, W267

Cannabis Dependence................M216, M225, T185, T220, T234

Cannabis Use................8.3, 29, 29.2, 29.3, M228, M236, T265

Cardiovascular................M110, W100

Cardiovascular Disorders................W166

Cariprazine................T163, T165

Cas9................35.1

Caspase Cascades................M258

Cat................W66

Catecholamine Depletion................M42

Caudate................M169

Causal Modeling................53.4

CB1................46.1

CBT................T111

Cdk5................15.4

Ceftriaxone................M152

Cell Adhesion Molecules................22.1, W166

Cell Transplant................10.3

Central Amygdala................W221, W223

Central Autonomic Network................W89

Central Nervous System................T211, W129

Central Nucleus Of The Amygdala................40.4

Cerebellum................51.1, 51.2, 51.3, M156, T143

Cerebral Blood Flow................M28, M42, T267

Cerebrospinal Fluid................M65, W181, W218

CESD Score................T119

CGRP................T155

Child Offspring................W35

Childhood Adversity................15.1, T136, W81

Childhood Maltreatment................23.3, 60.3, W6, W109

Childhood Trauma................16.1, T11, T81, T89, T242

Childhood-Onset Schizophrenia................T191, W205

Children................42.2, M24, W27

Children and Adolescents................M21, M31, M32, T9, T14, T84, W35

Chimeric Protein................W266

Choice................W252

Choline................M266, T90

Cholinergic Function................M149

Cholinergic Syste................m5, 5.1

Choroid Plexus................38.4

Chromatin................9.3, 52.2, W172

Chronic Mild Stress................1.1, T108

Chronic Pai................n19, T238, W147

Chronic Social Defeat................60.1

Chronic Stres................s60, T24, T121, T124, T127, W117

Cilia................M247

Cingulum................T12

Circadian Rhythm................T217

Classification................W99

Classifier................53.1

Clathrin Nanoparticles................W150

Clinical High Risk................42.1, M162

Clinical Practice................W77

Clinical Trial Design................M209, W127

Clinical Trial Methodology................M78, M134, M209, T125, W127

Clinical Trial Rating Methods................M78, T101

Clinical Trials................4.3, 45, M16, M61, M78, M81, M129, M174, M176, M181, T161, W71, W152, W262

Clozapine................M217, T168, T210

Clustering................W99

CNS Clinical Trials................M134, T240, W127

CNV................20.1

Cocaine................18.3, 36.2, 39.1, 43, 43.3, 43.4, 52.1, 52.3, M124, M229, M238, M256, M265, T46, T52, T105, T225, T227, T256, T257, W230, W257

Cocaine Addiction................3.1, M223, M241, M243, M259, T48, T57, T61, T240, T242, T247, T252, T258, T262, W228, W237, W252

Cocaine Seeking................54.3, M227, M232, M250, T233, T239, W234, W263

Coexpression Network................50.3, T26

Cognition................4.3, 8.2, 17, 17.3, 24, 34, 36.4, 49.2, 51.1, 51.2, M116, M156, M168, M208, M255, T88, T91, T160, T166, T167, T175, T185, T207, T210, T251, W174, W179, W208, W211, W212, W258

Cognitive Aging................M2

Cognitive Control................24.3, 61.2, M212, T16, T111, T192, W116, W174

Cognitive Control Network................61.1

Cognitive Decline................17

Cognitive Disorder................29, 48

Cognitive Enhancement................M138, M145, T145, T197, W189

Cognitive Functionin................g8, 8.3, M60, M140, W12, W33

Cognitive Impairments................T93, T178, T181, W120

Cognitive Neuroscience................T16

Cognitive Training................M145, W182

Cognitive/Emotional Task Performance................W50

Cognitive-Behavioral Therapy................M55, T25, T143, W142

Colony Stimulating Factor-1................T21

Community Based Family Study................42.1

Community Detection................T32

Co-Mobidity................T223

Co-Morbid................T196

Complement................T141

Complex Systems................53.4

Complicated Grief................W2

Compulsive Eating................T100

Compulsive Models Of Drug Use................T259

Compulsivity................M242, M254

Computational Modeling................3.4, 11.3, W190

Computational Neuroscience................11.1, 11.4, T241, T244

Computational Psychiatry................11.2, 11.4, 53, M230, W79, W190

COMT................T92, W152, W195

COMT Gene................W8

COMT Inhibitor................M138, M172

Conditioned Cues................W225, W253

Conditioned Place Preference................9.3, W226

Conduct Problems................30.2

Conflict Monitoring................W112

Connectivity................3.4, 42, 42.4, T9, T36, W42, W72

Connectivity-Based Parcellation................T43, T252

Connectome................M14, W138, W186

Context................39.2, W17

Continuation Phase................M80

Coping................W86

Copper Metabolism................M210

Corollary Discharge................W170

Cortical Circuit Development................59.2, T170, W213

Cortical Dysplasia................58.1

Cortical GABA................16.1, W52

Cortical GABA Transaminase................M157

Cortical Inhibition................48.2, T113

Cortical Maturation Delay................M47

Cortical Plasticity................4.4, 22.3, M26

Cortical Thickness................W109, W159, W177

Cortico-Mesolimbic Couling................W171

Corticosteroids................M2

Cortico-Striatal Circuit................T172, W216

Cortico-Striatal Plasticity................T143

Corticotropin-Releasing Factor (CRF)................40.4, T69, W221, W266

Cortisol................M73, M137, M238, T49, W53

Cortistatin................T83

COX-1 and COX-2................W1

CPP................W257

CPP-115................M157

Craving................M264, T151, T220, T257, W232, W252

C-Reactive Protein................M100

CREB................26.1

CRHBP Knockout Mice................W266

CRISPR................35.1, 35.3, T110, W148

CRMP2................T193

Cross-Generational Transmission................57.2

Cross-Sensitization................T223

CRP................38.2

CSF................W135, W220

CSF Biomarkers................32.1

Cue Reactivity................M239, T227

Cue Reinstatement................M250

Curriculu................m28, W125

CUS................M119

Cyclobenzaprine................W134

CYP2C19................M69

Cytochrome P450s................W144, W145

Cytokines................31.1, 58, 58.4, M57, M192, T52, T128, T168, W76, W181

D

D1 Dopamine Receptor................s51, M250

D1-D2 Dopamine Receptor Heteromer................M245

D2 Dopamine Antagonists................T179

D2 Receptor................54.1

D3 Receptor................M182

Dab................155.1

Dacc................M45, T71

D-amino Acid Oxidase................57.1

DAT1 Gene................M253, T254

Data Integration................50.4

Data Sharing................M134, T80

Data Transparenc................y45

DBS................M96

De Novo Mutation................T97

Death Domain................M258

Death Receptor Expression................M258

Decision Making................12, 12.1, 41.4, M228, M240, M248, W46, W227, W242

Deep Brain Stimulation................6.3, 21.1, M67, M95, T98, T122, W13, W54, W116, W143

Default Mode Network (DMN)................21, 21.4, T18, T268, W21, W24

Delay Discounting................M230, T219

Delta9-Tetrahydrocannabino................l8.2, T224

Deltafosb................M256

Dementia................T156

Dendrite................M247

Dendritic Spines................58.2, M175, M191, M223, T67, T222, W200

Dendritic Translation................14.4

De-Novo................M25

Dentate Gyrus................M75, T20, T79, W20, W62

Depression................1.2, 5.1, 5.2, 5.3, 6.4, 9, 9.2, 14.1, 14.2, 14.3, 15.1, 15.4, 16, 17.2, 21.2, 21.3, 32.4, 33, 40.1, 48, 56.4, 57, 57.4, 60.1, 61.3, M50, M52, M53, M57, M60, M61, M62, M63, M66, M68, M69, M71, M72, M75, M82, M89, M91, M100, M106, M108, M123, T21, T22, T27, T32, T78, T106, T107, T109, T111, T115, T118, T124, T128, T132, T138, T140, T141, W48, W51, W61, W65, W67, W71, W75, W76, W79, W85, W87, W92, W95, W96, W100, W104, W114, W123, W263

Desensitization................T51

Development................59, M198

Developmental................7

Developmental Pharmacology................M86

Developmental Psychopathology................M28

Developmental Trajectories................34.1

Dextromethorphan/Quinidine................W74

Diabetes................M148

Diet................W137

Diet Induced Obesity................M44

Diffusion Spectrum Imaging................M215

Diffusion Tensor Imaging................M59, M94, M99, M100, M162, M224, M259, W161

Diffusion Weighted Imaging................M45, T79, T192

Dimensional................W30

Dimensions Of Psychosis................W203

Disability................M207, W107

DISC................127.1, T172, T212, W207

Disease Model................M196

Disinhibition................W157

Disruptive Mood Dysregulation Disorder................W124

dlPFC................T45

DNA Methylation................9.4, 55.4, M62, M104, M191, T17, T30, T39, T56, T177, W98, W230, W240

Domestication................W66

Dopamine................11.2, 24, 24.2, 31, 31.1, 36.1, 36.3, 36.4, 41.4, 44.1, 54.1, 55.4, 60.1, M1, M46, M54, M138, M169, M193, M194, M211, M220, M232, T24, T55, T58, T59, T61, T163, T165, T179, T181, T186, T188, T202, T233, W45, W69, W86, W131, W159, W194, W201, W246, W247, W254

Dopamine (D2, D3) receptors................M264, T169, T179, W140, W194

Dopamine D1-D2 Receptor Heteromer................M256

Dopamine D2 Receptor................W249

Dopamine D3 receptors................W106

Dopamine Receptor Type 2-Expressing Striatal Medium Spiny Neuron................T157

Dopamine Receptors................51.1, M245

Dopamine Transporter................M260, T17, T246

Dopaminergic System................T188

Dorsal Attention Network................T44

Dorsal Raphe................7.1

Dorsal Raphe Serotonin Neurons................M84

Dorsal Striatum................54.2, W47, W222

Dorsolateral Prefrontal Cortex................M117, M249, W28, W177

DRD2................W236

DREADD Receptor................51.1

DREADD................s13, M244, T239

Drive For Activity................W23

Drug Abuse................M263, W258

Drug Cues................M243

Drug Discovery - New Approache................s25, 25.1, 25.2, 33, 49.4, M51, T148, T228, W73, W151

Drug Discovery/Development................W126

Drug Naive................T84

Drug-Protein Interactions................M152

Drugs................W94

D-Serine................43.3, 56.2, 57.1

DTI................M79, T12, W103, W114, W149

Dynamic Connectivity................3.2, 41.3, M14

Dynorphin................M232, T47

Dysbindin................M205, M210

Dyskinesia................M154

Dyspnea................T1

E

Early Life Stress................9, 9.2, M57, M64, T23, W6, W39, W98, W100, W121

Early Parental Loss................T205

Early Phase Drug Development................M11

Early Psychosis................10.1, M190, W186, W214

Early Rearing................W39

Eating Disorders................M43

eCOA................M165

Ecological Momentary Assessment................M73

ECT................21.3, M70, M217

EE................G16, 17.3, 36.3, 36.4, 41.1, W219

EEG Biomarkers................21.3, M14, M236, M243

Effect Size................M78

Effective Connectivity................M70

Efficacy and Tolerability................W58

Electric Field Modeling................W36

Electroconvulsive................W143

Electroconvulsive Therapy................6.4, M88, T117, T123, W96

Electroencephalography................M201

Electron Microscopy................T38

Electronic Cigarette (E-Cigarette)................T151, T226, T234

Electrophysiology................13.3, M5, M15, M30, M84, M184, T45, T50, T163, T166, T216, W56, W139, W167, W221, W222, W253

EMBARC................W99

Emotion................T175

Emotion Perception................W191

Emotion Processin................g30, M114, M200, W110

Emotion Regulation................11.4, M79, T14, T16, W55, W64

Emotional Reactivity................W12

Emotional Response Inhibition................T11

Endocannabinoids................8.4, 31, 31.3, 46, 46.2, 46.4, M190, M226, T5, T72, T127, T248, W199

Endogenous Opioids................T129, W83

Endophenotypes................W203

Endpoint Reliability................M165

Energy Homeostasis................W23, W62

Engram................W20

ENIGMA Working Group................M47

Entropy................M127

Environmental Enrichment................9.4, 58.3

Environmental Risk Factors................T205, W31

Epidemiology................60.3, M91, M235, M237, W219

Epigenetic Regulation................55, W172

Epigenetic................s2, 2.3, 5.3, 7.2, 9, 9.2, 9.4, 15, 15.4, 18.4, 31.4, 39.3, 50.1, 52, 52.1, 52.3, 57, 57.1, 57.2, 57.3, 57.4, M49, M64, M265, M266, T39, T126, T187, T221, T225, T262, W39, W100, W240

Epilepsy................M30, T83, W154

Episodic Memory................M36, T81, W79

Epistasis................W80

eQTL................20.3

ER Stress................W25

ErbB4 Pathway................59.2

ERK................T26, T85

ERP................W170, W189

Escitalopram................M85

Escitaropram................M69

Esketamine................56, 56.3, 56.4, M113, M115, M121, T134

Estradiol................18.3, 46.2

Estrogen................T64

Estrogen Receptor................7, 7.1, 18.4, W25

Ethanol................T260

Ethanol-Seeking................W225

Ethics................35.3, M67, M142

Event Related Potentials................M212, M216

Evoked Response Potential................24.4, M214

Excitabilty................W111

Excitatory Synapses................14, 22.1, 22.3

Executive Function................M198, W5, W186

Exercise................T76

Exome Sequencing................T249

Expectation................11.3

Experimental Design................W92

Experimental Therapeutics................33.4, 52

Extended Amygdala................26.2, M13

Extended Reward Network................41.1, 41.2, T146

Externalizing Disorders................42.3

Extinction................39.2, 39.3, M92, T227

Extinction Learning................M136, M263

Extinction Recall................M136

Extracellular Matrix Protein................s55

Extracellular Vesicles................T142

Eye-Tracking................M243, W32

F

Face Emotion Processing................T44, T117, W124, W169

Facial Expression................53.2

Familial Risk................W236

Fast-acting Antidepressant................W62

Fatigue................T152

Fatty Acids................W43

Fear................18.4, M7, M10

Fear Conditioning................7.4, 11.3, 12.2, 26.3, M6, M92, T3, T8, T66, T71, W16, W19, W70

Fear Extinction................26.3, 39, M18, M20, T3, T5

Fear Generalization................26.3, W20

Fear Memory................39.3

Fear Renewal................M136

Fear-Potentiated Startle................W19

Female................M124

Ferret................W206

Fetal fMRI................M143

Fetal Neurobehavior................M39

Fetal Programming................7.3, W265

Fibroblasts................49.3

First Episode Schizophrenia................M199, T40, W174, W196, W198, W216

First-Episode Psychosis................T182, W173, W208, W217

FKBP5................M106

Fluoxetine................M124

fMRI Biomarkers................34.3

fMRI Effective Connectivity................40

fMRI Functional Connectivity................11.1, 13, 21.4, 29.2, T196

fMRI Negative Affective Stimuli................7.3

fMRI Resting State................41.3, M110, M159, T162, W149

FMRP................T201

Food Preferences................M41

Food-Reinforced Instrumental Task................T157

Forced Swim Test................M54, M72, T112

Fox................W66

FRET................M256

Frontostriatal................21.2

Fronto-Striatal Networks................M17, T184

Functional Capacity................T190, T197

Functional Connectivity................13.4, 30.2, 30.3, M143, M186, M234, T43, W210

Functional Magnetic Resonance Imaging (fMRI)................3.1, 3.3, 11.3, 16, 16.2, 30.2, 30.4, 40.3, 41.1, 54.1, 61.2, M17, M34, M40, M43, M61, M68, M88, M100, M103, M108, M114, M127, M131, M132, M172, M178, M200, M221, M239, M242, M253, M262, T9, T11, T15, T32, T54, T60, T62, T71, T75, T106, T117, T137, T173, T191, T227, T246, T268, W16, W17, W41, W55, W64, W69, W124, W137, W158, W174, W195, W197, W198, W201, W242, W247, W252, W260

Functional Network Connectivity................M98

Functional Neuroimaging................41.2, 61, M145, W12, W76, W89, W115, W138, W145

Functional Organization................49.1

Functional Outcome................M207

Functioning................T160, W33

Funding................37

G

G Protein................M251

G Protein Coupled Receptors................M187, W94

G Protein Signaling................5

GABA................4, 4.4, 10, 13.3, 14, 46.1, 48, 48.1, 48.4, M6, M50, M97, M144, M179, M195, T70, W133, W201

GABA Neuron................M193

GABAA................48.3

GABA-A Receptors................M184, T221, W151

GABAergic Interneurons................10.2, 10.3, 14.1, 27.2, T83, W117, W131, W222, W225

GABRA2................M267

Gabra5 Conditional Knockout Mice................48.3

GAD................T177

Gambling................W45, W46

Gambling Disorder................M240, T57

Gamma Oscillation................24, T165, T183

Gamma Oscillation; Clinical Symptom Type and Severity................T190, W189

Gaussian Mixture Model................T166

Gaze Fixation................W27

GC-Insensitive Monocytes................31.2, W11

Gene Association................W179

Gene Editing................35.3

Gene Environment Interaction................20.2, 38.2, M167, M267, W43, W121

Gene Expression................50.1, M27, M49, M126, T30, T177, T230, W34, W177, W193, W195, W228, W237

Gene Network Analysis................T10, T56, T228

Gene Set Analysis................W80

Generalizability................M129

Genetic................T41

Genetic Architecture................W161

Genetic Correlation................W4

Genetic Mouse Models................2.3, 59, 59.1, M241, T42, W34, W156

Genetic Risk Factor................T37

Genetic Testing................M37

Genetic Variability................M140, T213

Genetics................20.2, 40.1, 50, 50.4, 60, 60.3, M23, M25, M30, M160, M257, T178, T204, T261, W144, W212

Genome-Editing................35.1

Genome-Wide Association................W187

Genome-Wide Association Studies (GWAS)................60.2, M140, M257, T66, T100, T119, T213, T236

Genomics................5.4, 20.3, 25, 25.3, 50, 50.1, 50.4, M52

Geriatric Depression................M126

Ghrelin................W82

Giftedness................M25

Ginkgo Extract................T93

GLP-1 Receptor Agonist................T186

GLT-1................T256, W230

Glucocorticoid Receptor................12.3, M106, T30, T70, T128, W60

Glucocorticoids................M7, M77, T10

Glucose Metabolism................W158, W184

GluN2A Recepter Subunit................T91

Glutamate................14, 16.1, 31.1, 32.4, 33, 33.2, 33.3, 43, 43.1, 43.3, 43.4, 46.1, 59.1, M32, M50, M54, M128, M179, M195, M199, M205, M213, T23, T40, T70, T78, T86, T89, T207, T251, T268, W74, W196, W210

Glutamate Gaba................16.3, M125, M203

Glutamate Homeostasis................M152

Glutamate Receptor Activity................M12

Glutamate Receptor Function................55

Glutamatergic Synapses................43.2

Glutamatergic Transmission................M44, M262

Glutathione (GSH)................4, 4.3

GLYX-13................14.3, 33.1, T78

Gonadal Hormones................18, 18.2, W22

GPCR................49.4, T148, W102, W246

GR Chaperone................M20

Graph Theory................24.3, W109, W158

Gray Matter Concentration................T242

Gray Matter Density................M188, W204

Gray Matter Volumes................W236

Group ICA................3.2

Growth Mixture Modeling................W180

GSK3................W111

GT-tg Mouse Model................W150

Gut Microbiome................1, 1.1, 1.2, 1.3, 1.4, 18.3, M102, T88, T226, W67

Gut-Brain Axis................38

GWAS LOCI................20.4

Gyrus Rectus................W42

H

Habenula................M24, T127, T235

Habit................46

Habituation................T158

Hallucinogens................M131, W168

Haplotypes................M267

Harm Reduction................W262

HDAC................T225

HDAC 2/3................T221

Head-To-Head Clinical Trial................M231

Healthy Subjects................M182, W202

Heart Rate Variability................W10, W89

Heritability................60.3, M189, W219

Heroin................M229, T232

High Frequency Oscillations................W171

High Throughput Screenin................g25

High-Throughput................25.3

Hippocampal Function................10.1, 15.2, W168

Hippocampal Hyperactivity................2.4

Hippocampal Subfields................M38, W205

Hippocampal Volume................10.1, M171, W7, W205

Hippocampus................2.1, 9.4, 38.4, 48.1, 57.1, M62, M88, T12, T27, T39, T81, T136, T139, W113, W117, W121, W196, W210

Hippocampus Shrinking................W108

Hippocampus-Mpfc Pathway................24.1, T6, T149

Hispanic/Latinos................T65

Histone................8.2

Histone Methylation................7.2, 9.1, 52.2

HIV................M19, M60, M255, T13, T128

HIV Associated Neurocognitive Disorder................W150

Homeostasis................T216

Homeostatic Synaptic Transmission................14.4

HPA................M137

HPA Axis................12.3, 23.4, M74, M123, T218, W39, W60

HPSC................25.3

Hub Analysis................M45

Human Brain Slice................T183

Human Clinical trial................M35, T78

Human Embryonic Stem Cells................10.4

Human Genetic................W266

Human Laboratory Study................M268, T264

Human Neuroimaging................3, 6, 7.4, 24.3, M3, M236, M237, M240, T13, T88, W7, W30, W40, W49, W162, W186, W251

Humans................T145, W139, W199, W226

Hunger and Satiety................M40, T102

Huntingtin................T172

Hydroxynorketamine................14.2, 56.2, W78

Hyperarousal................T218

Hypothalamic-Pituitary-Adrenal Axis................M2

Hypothalamus................M155

Hypoxia................M72

I

IL17................58.1

IL-1b................T108

Imaging................T203, W164

Imaging Genetics................T180, T246, W145, W201, W203

Immune................38.3

Immune Markers................58, M192

Immune Mechanisms................M101, T10, T29, W31

Immune Modulation................M126

Immune System................W81

Immunological................T187

Importance of Religion................W108

Impulsive Sensation Seeking................41, 41.1

Impulsiveness................T258

Impulsivity................M128, M230, M252, T57, T103, T171, T259, W13, W47, W81, W159, W238

In Vitro Neuronal Differentiation................25.1

Inattentive Symptoms................T102

Inbred Mouse Strains................T42

Incentive Motivation................61.3, T50, W201

Incentive Salience................3.4, 12.3

Individual Differences................3.1, 12.3, M131, W56

Individual Items................T195

Individual Items of Positive and Negative Syndrome Scale................T173

Induced Pluripotent Stem Cells (iPSCs)................10.4, 20.1, 25, 25.1, 25.2, M109, M183, W106

Infancy................M7, T88

Infant................42, 42.3, M39, T90

Infection................47, 58.2, M192, T90, W136

Inferior Frontal Gyrus................W21

Infertility Treatment................W88

Inflammasome................M102

Inflammation................31.1, 31.3, M26, M52, M83, M85, M89, M100, T128, T168, T208, W3, W76, W87, W92, W96, W104, W146, W160, W183, W237

Inflammatory Markers................31, 38.1, 38.2, W65

Inflammatory Pain................M130

Inflammatory Response System................T206

Infralimbic Cortex................39, 39.1, M118

Inhibition................W20

Inhibitory Control................3.1, 48.1, M40, M234, T15, W47

Inhibitory Neurotransmission................W26

Inhibitory Synaptic Transmission................14.4

Insight................W157

Insoluble Proteins................W176

Insomnia................M71, T218

Insula................M6, T1, W75, W254

Insula Connectivity................W251

Insulin................M44, W101

Insulin Resistance................M107, T211, W38, W62

Insulin-Like Growth Factor 1................M44, T67, T212

Integrin................T222

Intellectual Disability................2.2

Intelligence Quotient................M127

Intergenerational Transmission................W39

Interleaved TMS/fMRI................T4, W103

Internal Capsule................M95

Interoception................T1, W75

Interpeduncular................M244

Interpeduncular Nucleus................T235

Intracerebroventricular................T211

Intracranial EEG................W149

Intracranial Self-Administration................W223

Intracranial Self-Stimulation................M260

Intranasal................T134

Intravenous Drug Self-Administration................T46

Intravenous Immunoglobulin................47.4

Irritability................30.2

Isomirna................W188

Item Response Theory................32.2

IV Alcohol................M233

J

Japanese................M69

K

Kappa Opioid Receptor................M130, T47, T230, T247, W228, W246, W249

KCC2................W151

Ketamine................6.1, 6.2, 14, 14.2, 14.4, 15.2, 23.2, 32.4, 33.2, 56.2, 56.3, 56.4, M16, M56, M66, M80, M92, M109, M114, M115, M121, T19, T25, T31, T33, T112, T135, W59, W78, W97, W101

Kinase Inhibitor................T255

KO Mice................M112

Kv3 Family................27.1, T161, T181, T183

Kynurenine................W57

Kynurenine Metabolism................W92

L

Lactate................T200

Lactate Shuttle................M197

Language................T88

Large Scale Networks................3, M45, W138, W154

Late-Life Depression................M99, M103, T63, T65, T123, T139, W68, W120, W135

Latency of Acoustic Startle................T204

Lateral Habenula................M41, T239

Lateral Hypothalamus................M41

Lateral Orbitofrontal Cortex................T99

Lateral Septum................W131

L-DOPA................M154

Learning................17.1, W69

Learning And Memory................31.4, 59, M49, T79, T133, W22

Lethality................W248

Leukocyte Telomere Length................M3, T124

Life Stress................15

Light Therapy................M63, T107

Limbic Cortex................10, M74

Linguistic................53.1

Lipid Rafts................W102

Lipids................M90

Lipoprotein Receptors................55.1

Lisdexamfetamine................T101, W129

Lithium................M116, T62, T115, T156

Lithium Treatment................T62

Local Field Potentials................6.3, T98

Locomotion................T249

Locus Coeruelus................M63, T109

Long Noncoding RNA................T35

Long Term Potentiation................57.1, W241

Long-Acting Injectable Antipsychotic................T116

Longitudinal................M162, T84, W174

Longitudinal Imaging................W40, W149

Long-Term Depression................46.3, T224

Long-Term Potentiation................M171, T149

Low-Dose Antagonism................T145

Lurasidone................M81, W58, W91, W105, W117, W215

Lymphocytes................T85

Lysergic Acid Diethylamide................M187

M

Machine Learning................11, 53, 53.2, M91, T98, W142, W161

MADRS................W93

Magnetic Resonance Imaging (MRI)................6.4, M186, M188, T150, T265, T267, W29, W40, W72

Magnetic Resonance Spectroscopy................M6, M144

Magnetic Seizure Therapy................21, 21.3, T28

Maintenance Treatment................M163, T116, T199, W105

Major Depression................41.2, 48.4, M56, M65, M92, M102, T29, T112, T117, T123, W82

Major Depressive Disorder (MDD)................21.1, 41.3, M32, M55, M83, M88, M101, M104, M105, M114, M117, M119, M120, M129, T23, T25, T26, T31, T119, T125, T129, T134, T135, T136, T137, W24, W53, W73, W74, W78, W83, W89, W91, W93, W97, W99, W108, W118

MAM................T208

Mania................W91

MAPK................................................................55.1

Marijuana................8, 8.1, M132, M235, M245, M261, T250, T253, W258

Massage................T152

Maternal Abuse................2.3

Maternal Behavior................42.4, M7, M155

Maternal Deprivation................13.1

Maternal Immune Activation................58.1, 58.3, M39

Maternal Sensitivity................M108

Maternal Separation................13.2

Matrix Metalloproteinase-9 (MMP-9)................T222

Mechanism of Action................M58

Medial Amygdala................W61

Medial Forebrain Bundle................M67, M96, T122, W54

Medial Geniculate................T36

Medial Prefrontal Cortex................12.2, 13.2, 24.4, M171, M248, T8, T55, T131, T226, W94

Medication................M8

Medication Adherence................W127

Medication Resistance................M217

Medicinal Marijuana................8.1, M235

Mediodorsal Thalamus................24.4, M15

Medium Spiny Neurons................54.3

MEG................M214

Mega-Analysis................M47

Melanocortin................W255

Melatonin................T112

Memantine................W189

Memory................52.2, T149, W4

Memory and Learning................2.1, 48.3, 59.4, T27, T69

Memory Consolidation and Extinction................39.4, T3

Memory Encoding and Retrieval................2, W17, W168

Memory Organization................T133

Memory Reconsolidation................W234

Menopause................15.1

Mental Disorder................M183, T37

Mental Health................53.3, M133

Mental Set Shifting................M261

Menthol................W264

Meta-Analysis................M101, T103, W6, W12

Metabolic Defect................M197

Metabolic Side Effects................T186

Metabolic State................T15, W62

Metabolic Syndrome................36.1

Metabolism................M68, T86, W147

Metabolites................W141

Metformin................W38

Methamphetamine................36.2, 52.2, T234, T241, T261, W232, W250

Methotrexate................M174

Methylation................M253, W236

Methylphenidate................M29, T147, W245

Metyrapone................T68

Mexican Population................T194

Mglu 2/3................T95

Mglu2/3 Antagonist................M251

Mglur5 Receptors................M128, W44

Mice................M82, T20, W8

Microbiota-Gut-Brain Axis................W233

Microdialysis................27.2, T46, W45

Microglia................31.1, 58.4, T21, T209, T217, W11, W213

Microglia Priming................M33, M77

Microglial Activation................T260

MicroRNA (miRNA)................5.4, 50.3, 52.1, 60.2, T109, T142, T262, W188

Microtubule................W148

Migraine................T155

Mild Cognitive Impairment................T94

Mild Cognitive Impairment Due To AD................M36, W38

Mild Traumatic Brain Injury................W130, W218

Mismatch Negativity................16.3

Mitochondria................54.3, M64, T38, T86

Mitochondrial DNA................M123

Mitochondrial Dysfunction................T93

Mixed Features................W91

MMN................W189

Mobile Health................W123

Mobile Technology................W51

Mode................l26

Model-Free and Model-Based Learning................11.2, T241

Molecular Mechanisms................56, T41

Monkey................36.4

Monoamine Oxidase-A................M160, T120

Monoamines................36, 36.3, 36.4, T120

Mood................M68, T102, W66

Mood And Anxiety Disorders................7, 33.4, M16, M49, T8, W73, W81, W111

Mood Disorder Subtypes................M98

Mood Disorders................7.3, 11, 23, M59, M166, T108, T156, W55, W86, W88

Mood Dysregulation................42

Mood Stabilizers................M93

Moral Judgment................30.3

Morphine................T51, W246, W249, W257

Morphology................M175, M247

Mossy Fiber................T209

Motivated Drug Taking................39.3

Motivation................24.2, 31, 41.4, M130, T105, T157, T198, W69, W165

Motor Activity................17.2

Mouse................W139

Mouse Behavior................M20, T42

Mouse Models................5.1, 5.2, 59.2, 59.3, M187

Movement Disorders................M150, M151

MR Imaging................T22, T139, W34

MR Spectroscopy................16, 16.2, T23, T89

mRNA Expression Gradients................M203

MRS................33.2, 33.3, M179

mTOR................14.3

Multi-Electrode Arrays................25.2

Multi-Episode Schizophrenia................T182, T192

Multimodal Neuoimaging................23, 41

Multivariate................W142

Mu-Opioid Receptors................M51, M254, M260, T51, W83

Muscarinic Acetylcholine Receptor................M177, T45

Myelin................W185

Myelin Imaging................23.3

Myocardial Infarction................T156

Myoinositol................T104

N

NAc core................T58

N-acetylaspartate................M199, W163

N-acetyl-cysteine................4.3

NAD+ and NADH................4.2

Naltrexone................M139, M231, T254, W229, W232, W260

Negative Affect................46.2

Negative Symptoms................M188, M218, T167, T168, W165

Neruopil................M196

Nest-Building................M220

Network Analysis................34.2, 50.2, T180

Network Science................24.3, 53.4

Networks................M22

Neural Circuitry................T37

Neural Circuits................51.3, 61, M224

Neural Complexity................T162

Neural Development................T97

Neural Network Connectivity................T32

Neural Populations................T2

Neuregulin-3................59.1, 59.2, W241

Neuroactive Steroid................M76

Neuroanatomy................M13, M45

Neurobiology................M106, M108

Neuroblast................13.1

Neurochemistry................M190

Neurocircuitry................T154, T184, W153, W164

Neurocircuit................s18, 18.2, T110

Neurocognition................41.2, M189, T65, T123, T169, W107, W180

Neurodegeneration................M3

Neurodegenerative Disease................T86, T95, W3

Neurodevelopment................55, M196, T96, T154, T192, W28, W153, W206

Neurodevelopmental Disorders................M62, T86, W29, W30, W132

Neuroeconomics................T144

Neuroendocrine................46

Neuroendocrine Responses................W9

Neurogenesis................T79, W95

Neurogenesis Enhancers................M5

Neurogranin................W37

Neuroimaging................34.2, 42.2, M42, M47, M79, M170, M198

Neuroimmune................31.4, M49, T21, T260

Neuroimmune Interaction................38, 47.4, T52

Neuroimmunology................47.1, 58.2, T142

Neuroinflammation................58.4, M77, M83, M111, W1, W259

Neurological Disorders................M133

Neuromodulation................17.1, T107, W116, W178

Neuron Subtypes................49

Neuronal Epigenome................T176, W193

Neuronal Maturation................13, 13.3

Neuronal Tracing................13

Neurons................25.3, M196, T216

Neuropathic Pain................33.1

Neuropeptide Y................M11, M65

Neuropeptides................M104, T231

Neurophysiology................24.1, 48.2

Neuroplasticity................17, 48.2, M249, T21, T93, T126

Neuropsychiatric Disorders................38.1, 59.4, T27

Neuropsychiatry................W152

Neuropsychology................38.3

Neuropsychopharmacology................W126

Neurostimulation................6, 21.1, 51.2, T118

Neurosurgery................W14

Neurotechnology................W150

Neurotensin................M9

Neuroticism................W57

Neurotransmitter Release................55.3

Neurotransmitters................M195

Next Generation Sequencing................5.2, W193

Nicotine................52.3, M229, T147, T235, T268, W224, W245, W253, W259, W264

Nicotine Addiction................M266, T237, T243, T251, T266, W251, W262

Nicotine Dependence................M244, M268, T219, W241, W262

Nicotinic................T64

Nicotinic Acetylcholine Receptors................5.1, M244, T145, T235, W261

Nitric Oxide Donor................W209

Nitrous Oxide................W95

NMD................A14, 33.2, 43, 43.3, W57

NMDA Antagonists................11.1, 33.2, W74, W171

NMDA Glutamate Receptors................W106

NMDA Receptor................2, 2.3, 13.2, 14.1, 27.1, 33.1, 33.4, 43.2, 55.2, M58, M193, T91, W189, W238

NMDA Receptor Knockdown................M197

Non Pharmacological Interventions................M108

Non-Human Primate................M147, M182, M201, T232

Non-Pharmacological Therapy................W15

Non-Suicidal Self-Injurious Behavior................32.3

Noradrenaline................M219

Noradrenergic................M7, M158, T253

Noradrenergic System................W247

Norepinephrine................60.1, W218

Novel................M166

Novel Therapeutics................33.4, M177, W126

Novel Tool................M133

Novelty Seeking................W159

Nucleus Accumbens................15.3, 52.3, 54.3, M44, M70, M226, T47, T60, T224, T244, W238, W240, W244, W250

Nucleus Accumbens Shell................T58, W263

O

Obesity................61.3, M41, T99, T146, W137, W147

Obsessive-Compulsive and Related Disorders................W14

Obsessive-Compulsive Disorder (OCD)................33, 33.4, 47, 47.1, 47.2, 61.1, T74, T78, T143, W13, W16, W18, W21, W142

Obstetric Complications................M167

Off-Target................35.1

Oligodendrocytes................23.3, T100

Omega-3 Fatty Acid................T131, W50, W77, W214

Opiates................M139

Opioid Antagonist Treatment................W243

Opioid Dependence................19, M230, M231, W243

Opioid Overdose................19

Opioid System................M51, T49

Opioid Tolerance................W246, W249

Opioid Withdrawal................44.4

Opioids................57.3, T53, T238, T257

Opposite Defiant Disorder................M29

OPRM1 A118G................T114

OPRM1 Gene................T254

Optogenetics................24.1, 24.2, 27.2, 39.1, 40, 40.4, 51, M10, M15, M84, M164, T6, T55, W18, W70, W221, W247

Orbitofrontal................M222

Orbitofrontal Cortex................T242, W41, W253

Orexin................T48

Orexin Receptor Antagonist................T48, T218, W71

Organic Cation Transporters................T229

Outbred Mice................T66

Outbred Rats................1.1

Oxidative Stress................4, 4.2, 4.3, 4.4, 27.3, M204, W141, W176, W265

Oxytocin................15.3, 44, 44.1, 44.2, 44.3, 44.4, M35, M122, M146, M155, M251, T34, T75, T82, W2, W19, W122, W198, W235

P

P11................M89

P2X7................M111, T108

P38 MAPK................M153

P50................T90

PACAP................7.4, 26, 26.1, 26.2, 26.3, 43

Pain................3.3, 11.3, M213, W75, W255

Pain Observation................30.3

Palpitation................T1

PANDAS................47.1, 47.2, 47.3, 47.4

PANSS Inconsistencies................M165

Parental Age................W35

Parkinson's Disease................54.1, 54.2, M65, M89, M154, T147

Parvalbumin................4.4, 27, 27.3, 27.4

Parvalbumin Interneurons................9.3, T38, T181, T183, T217, W244

Patch Clamp Recording................T105

Patch Foraging................M1

Paternal Stress................57.4

Pathology................M210

Pathophysiology................50.2

Pavlovian Conditioning................W56

PCaMKIIa................M205

Pediatric Acute-Onset Neuropsychiatric Syndrome................47, 47.1

Pediatric PTSD................W28

Pediatrics................61, 61.2, 47.2

Perception................M194, M208

Periaqueductal Grey (PAG)................12.2

Perineuronal Nets................4, 4.4, 27.4, T217

Peripartum................M122

Peripheral Blood Mononuclear Cells................M105, T130

Personality................40.2, M94, M103, M128, W14, W66

Positron Emission Tomography (PET) Imaging................8, 32.1, M12, M53, M77, M105, M111, M128, M133, M135, M144, M169, M182, M264, T17, T74, T169, T245, T248, W1, W113, W140, W155, W194

PET Study................W44

PFC................T251

PGE1................M148

Pharmacogenetic Response................T236, T254, W43, W173

Pharmacogenetics................40.4, M69, T114, T194, T246, W229

Pharmacogenomics................W68

Pharmacokinetics................T232

Pharmacology................M23, T115, W151

Pharmacotherapy................T104, T228, T240

Pharmacovigilance................W63

Phase III Trial................M173, M180

Phenotypic Screening................25, W161

Phenotyping................25.3

Phosphodiesterase-4 (PDE4)................M120

Phosphorylation................M175

Photoidentification................T2

Placebo................M163

Placebo Response................11, T73, T129

Placebo-Controlled Trial................T73

Placenta................7.2, M167

Plasticity................16.3, T34

POGZ................T97

Polydrug Use................M225

Polygenetic Risk Score................38.2, M167, W49, W173

Polygenic................T41

Polygenic Risk................50.2

Polygenic Risk Score................38, M140, T203, W3

Population and Single-Cell Scales................49.1

Population -Based................M142, W35

Population Genetics................T213

Positive Allosteric Modulators................W261

Positive and Negative Syndrome Scale................T195

Positive Emotion................60.2

Positive Mood................T32

Positron Emission Tomography (PET)................54.1, M68, M119, M120, M168, M209, W147, W254, W259

Postmortem................M197, W175

Postmortem Brain Tissue................23, 38, M106, M184, T164, T193, W3, W193, W200

Postmortem Human Brain................20.3, 27.4, M4, M38, M104, T39, T109, W144

Postpartum Blues................T120

Postpartum Depression................M76, M122

Posttraumatic Memory Deficit................M149

Poverty................42.4

Prader Willi Syndrome................M35

Precision Medicine for Depression................W68

Prediction................32.3, 53.3, M34, M185

Predictive Models................53

Predictive Validity................25.1

Predictors................W93

Predictors of Response................6.4, T31

Prefrontal Circuit................13.3, T135

Prefrontal Cortex................5.2, 7.1, 10.2, 12.1, M2, M15, M95, M138, M250, T14, T202, T235, T263, W116, W213, W238

Pregnancy................M122, M137, T90, T96, W63

Prenatal................M86

Prenatal Ethanol................M33

Prenatal Smoking................W231

Prenatal Stress................7.2, 42.3

Prenatal Stress-Immune Model................7.3

Prescription Opioids................19

Presynaptic Ca2+ signaling................55.3

Presynaptic Uptake................M151

Preterm................42.2

Prevention................32, T120

Prevention of Alzheimer's Disease................M5

Primary Neuron................M247

Prodrome................53.1, M185, T120

Prodynorphin................W250

Proenkephalin................W250

Progesterone................18.1, W231

Projection Targets................49.1

Proopiomelanocortin Neurons................M33

Propanolol................M158

Protein Complexes................W239

Protein Expression................T193

Protein Kinase C................43.2, T255

Protein Structure................22.2

Protein Structure and Function................22

Proteomics................W200

Proton Magnetic Resonance Spectroscopy................M32, M125, M157

Proximity Ligation Assay................M256

PSD95................2.2

Psychiatric Comorbidity................40.2, M125, M202, T125, T238, W48

Cognitive Function................W207

Psychiatric Disorders................W207

Psychiatric Genetics................20.3, M90, T159, W203

Psychiatric Measurement................32.2, T214

Psychopathology................W202

Psychopathology Patterns................T206, W35

Psychopharmacology................1, 6, M61, M209, T215, W125, W215

Psychophysiology................M19, W10

Psychosis................4.1, 10, 10.2, 10.4, 29.1, 34, 53.1, M53, M162, M215, M246, T39, T203, W185, W204, W210, W211

Psychosis and Memory................2.4

Psychosis Continuum................T160

Psychosis Risk................56.3, M188

Psychosocial Stress................42.1, M53, M227

Psychostimulants................9.3, 30.4, 44.1, 54.3, T229

Psychostimulation................W264

Psychotherapy................M8, T4

Psychotic Disorders................22, 53.2, M185, W184

Psychotropic Medications................T190

PTEN................10.4

Posttraumatic Stress Disorder (PTSD)................7.4, 12.2, 18.4, 33.1, 39, 39.4, 53.4, 59.4, M6, M8, M11, M12, M19, M56, M92, M127, M192, M219, T4, T8, T10, T67, T68, T72, T73, T111, T248, T256, W7, W8, W10, W109, W134, W218

PTSD Depression................T7

Puberty................M21, W26

Publications................45

Punishment................M248

Purkinje Cells................51

Pyramidal Neuron................T38

Q

QIDS-SR16................W93

QOL................T152

Quantitative Electroencephalography (qEEG)................11.1, T16, T28

Quantitative Trait Locus (QTL)................M20, T249

R

R-(-)-Ketamine................56, 56.3, M115, M118, M121

R-(-)-Norketamine................M121

Racemic Ketamine and Metabolites................56

Racial/Ethnic Minority Elderly................M142

Radiation Injury Non-Human Primate................M147

Radiotracer................M111

Randomized Clinical Trial................T73, T87, W134, W208

Randomized Trial................W192

Rapid Antidepressant................6.2, T135

Rapid Antipsychotic Augmentation................W209

Rat Model................T122

Rating Scales................T101, T214

Rats................T127, T145, T216, T250

RDoc................W72

Real-Time fMRI................W69

Recent Onset Psychosis................W216

Receptor Internalization................W194

Trafficking................W194

Recovery................T182

Recurrence Risk................W105

Redox Dysregulation................4.2, 27, T208

Reelin................55.1, 55.2, 55.3

Reinforcement................T50

Reinforcement Learning................T198, W79

Reinforcement-Based Decision-Making................30.2, M46

Reinstatement................26.2, 39.2, 39.4, M227, T243, W234

Rejection................W83

Relapse................39, 39.2, M42, M268, T25, T222, T239, W18, W93

Relapse and Hospitalization................T115

Relapse and Treatment Outcome................T53

Relapse Prevention................T195, W231

Religion................W128

Remifentanil................M229

Remote Assessment Solution................T195

Remote Memory................W20

Repeated Social Defeat................31.2

Repetitive Transcranial Magnetic Stimulation................T7, W36

Reproducibility, Design, Replication................25.1, T18

Research Domain Criteria (RDoC)................M136, T57, T111, W12, W52, W107

Residency Training................28, W85, W125

Resilience................60, 60.1, 60.3, M11, M18, T67, W24, W94, W141

Response Inhibition................16.2

Rest fMRI................3.2

Resting State................21.2, 21.3, M178, M214, T150

Resting State Brain Imaging................T226

Resting State fMRI................M70, M98, W24, W115, W119

Resting State Functional Connectivity................3.1, 6.2, 21, 21.1, M24, M39, M74, M107, M131, M169, T7, T18, T44, T62, T77, T80, T135, T143, T219, W13, W21, W99, W142, W211, W216, W245, W260

Resting State Intrinsic Connectivity................T146

Retina................M63

Reversal Learning................W26, W190

Reward................3.4, 18.2, 41.4, 54, M48, T60, W82, W223

Reward and Aversion................54.4, M130, T55

Reward Deficit................W115

Reward Devaluation................T99

Reward Neural Circuitry................41, 42.1, 61.3, M21, M253, T173

Reward Prediction Error................W41, W79

Reward Processing................T233

Reward Prospect................M240

Reward System................M43, M260, T105, W165

Reward-Based Decision-Making................M1, T53, T241, W112, W190, W252

Rhesus................W133

Rho Family GTPase................T149

Risk................M107, T30

Risk and Resilience................15.1, T53, T136

Risk-Based Monitoring................M165

Risk-Reward Paradigm................W112

Risperidone................M29, W214

RNA Sequencing................9.2, 20.3, 23.3, 38.4, M87, W80, W144, W156, W188

RNA-seq................20.4, 31.4, 49.1, M49, M117, T35, T100, T184, T208, W121

Roadmap................M8

Rodent................s26, M148

rTMS................21, 21.2, T113, W254

S

Safety................M150

SAGE-547................M76

Salience Network................T158, T173, W21

Schizoaffective Disorder................T162

Schizophrenia................2, 2.2, 4, 4.1, 4.2, 8.4, 10.3, 11, 11.1, 16, 16.2, 16.3, 22.1, 22.4, 24.4, 27, 27.2, 27.3, 27.4, 33, 33.3, 34.3, 36, 36.1, 36.4, 38.3, 50, 50.3, 51, 51.2, 55.4, 58, 58.2, 59.3, M161, M163, M164, M165, M166, M167, M169, M170, M172, M173, M174, M175, M176, M177, M178, M180, M181, M183, M184, M186, M189, M191, M192, M194, M198, M200, M202, M203, M204, M205, M206, M207, M208, M209, M211, M213, M216, M217, M218, M268, T36, T38, T41, T43, T45, T161, T162, T163, T165, T167, T168, T171, T174, T175, T177, T178, T179, T181, T185, T186, T187, T189, T190, T193, T195, T196, T197, T199, T200, T201, T202, T204, T205, T207, T213, T214, T215, T217, T237, W160, W161, W162, W163, W165, W166, W169, W172, W176, W177, W178, W181, W182, W183, W187, W188, W191, W192, W194, W195, W197, W200, W206, W209, W212, W213, W215, W241

Schizophrenia Genetics................38.2, M140, W179

Schizophrenia Prodrome................W170, W217

Synaptic Aberrations................2, 2.2, 22.1, 58.2, M184, T45, W213, W241

Technology................M55, M206, T197, W161

Schizophrenia-Like Behavior................59, M112, M171

Schizotypy................T160

Screening................32

Seizures................T156

Selectively Bred bHR And bLR Rats................T249

Self-Administration................44.1, 57.3, M48, M223, M227, M229, M244, T48, T224, T234, T243, T247, W256

Self-Directedness................M159

Self-Injurious Behavior................W143

Self-Other Processing................W197

Self-Relatedness................16.1

Semantic................53.1

Sensorimotor Gating................T172

Sensory Data................W123

Sensory Overload................22.4

Sensory Processing................W169

Serious Mental Illness................1, W136

Serotonergic Neuron Subtypes................49.1

Serotonergic Neurons................49.3

Serotonin................49, 49.3, 49.4, M57, M135, M153, M247, T126, W5, W76

Serotonin 1A Receptor................23.4, 49.2

Serotonin 1b receptor................M105, W47

Serotonin 2A................M131

Serotonin 5-HT2C Receptor................M259, W239

Serotonin 5-HT7................49.2

Serotonin and Norepinephrine Reuptake Inhibitor................W68

Serotonin Transporter................M153, W113

SERT................W155

Serum Levels................M181

Sex Differences................5, 7.2, 7.3, 12.1, 12.4, 18, 18.3, 31.4, 57.2, M3, T26, T68, T69, T146, T153, T233, W46, W55, W60, W61, W84, W87, W92, W98, W122

Sexual Dimorphism................5.3, 7, 12.2, 18.1, 46.2, M59, M97, M112

Sexual Sadism................30.3

Shank................322.4

Short-Term Synaptic Depression................M201

shRNA................W266

SIBAT................M113

Sigma 2................M218

Signal Transduction................5.2

Sign-Tracking................M226

Simulated Driving................M132

Simultaneous PET-MR................M144, T51

SK3 Calcium-Activated Potassium Channels................M84

Skin Conductance Responses................T71

Sleep................1.2, 36, 36.3, 36.4, M48, M71, M220, M221, T19, T68, T216, W220

Sleep Disturbance................M60, M219, T79, W192

Sleep Spindles................W219

Slow Oscillation................43.1

Smartphone-Based App................W123

Smoking................W187, W259

Smoking Cessation................M252, M255, W262

SNP................W179

SNX19................20.4

Sociability................T91

Social Anxiety................12.4, M14, M16, T125, W122

Social Behavior................15.3, 18.1, 51.1, M155, T82, T138, W61

Social Buffering................M10

Social Cognition................M146, T44, W197, W198, W243

Social Cognitive Skills Training................34.3

Social Communication................M158

Social Defeat Stress................12.3, T110, W122

Social Defeat................W11

Social Deficits................34.1

Social Functioning................15, 34.2, T87, T203

Social Interaction................26.1, M17

Social Isolation................M84

Social Stimuli................W32, W83

Social Stress................T59

Social Support................W235

Socio-Economic Status................W227

Somatic Mosaicism................20, 20.1, 20.2

Somatic Mutation................20.2, T164

Somatosensory Network................T146

Somatostatin................14.1, 14.4

Source Based Morphometry................30.3

Spatial Navigation................W168

Speech................53, 53.2

Speech Production................53.3

Spines................2.2

SSRI................1.3, M62, M72, M264, W82

Statistical Methods................M225

Stem Cells................10.2, 49, M196, W132

Stereotypic Behavior................T91

Stereotypy................W143

Sterols................M91

Streptococcus Pyogenes................47.3

Stres................s12, 15.1, M106, M108, T34, T202, W18

Stress Abnormalities................M33

Stress Models................M87, T22, T231

Stress Response Circuitry................M75

Striatum................9.3, 41.4, 54, 54.4, 57.2, M21, M253, T153, W194

Structural Covariance................M22

Structural MRI................29.2, T103, T180, W7, W28, W108, W179

Subcellular Fractionation................T201

Subclinical Psychosis................34.1, M178

Subcortical Shape Analysis................W108

Subgenual................M74, T144

Subgroups................T166

Subjective Cognitive Impairment................M5

Subjective Response................T264, W232

Substance Abuse................3, 9, T13, T240, T257

Substance Use................3.2

Substance Use Disorder................M265

Substance-Related Disorders................40.3, M59, M267, T248

Subthalamic Nucleus................W13

Subtypes................M170, T41

Suicidal Ideation................M113, W97

Suicide................23, 23.1, 23.2, 23.4, 32.2, 32.3, 32.4, M71, M73, M123, T19, T33, T109, T136, T138, T140, W50, W84, W128, W136

Suicide Assessment................32, T12, T134, W50

Suicide Behavior Severity................32.1

Superior Frontal Cortex................T201

Superior Longitudinal Fasciculus................M215

Susceptibility Genes................M257

Swine Model................T59

Sydenham's Chorea................47.3

Symptom Trajectory................M163

Symptoms................W160

Synapses................15, 22, 38.1, 58, 59.3, M183, M192

Synaptic Cleft................22.2

Synaptic Density................M119

Synaptic Function................58.3, W117

Synaptic Organizer................22.2

Synaptic Plasticity................2, 2.1, 5.3, 9.1, 15.2, 55, 55.4, 56.1, 59.1, M49, T61, T212, W244

Synaptic Protein Interaction Network................22.2

Synaptic Pruning................22.3, 58.4, T170

Synaptogenesis................22.1, 22.3

Synchrony................W222

Synthetic Cannabinoids................M246

Synthetic Psychoactive Cathinones................W248

T

TALEN................35.1

Tardive Dyskinesia Clinical Trials................M150

Target................34

Task-Based Functional Connectivity................M261

Tau................T63, W37, W130

TBI................M149, M219, W155

TBR1................13.1

TBX1................T92

Telomere................T140, W6

Temperament................M159

Temperature Regulation................W248

Th17................58.1

Th17 Cells................47.3

Thalamus................27.3, 27.4, T36, T174, T252, W119

Thalamus - Reticular Nucleus................27, 27.1, 27.2

THC................M245, T220, T267, W202

Therapeutic Drug Monitoring................M181

Therapeutics................4.1, 10

Therapy-Resistant Depression................M67, W54

Threat................40.3, T54

Threat of Shock................T54

Tianeptine................M51

Time................T176

Timing................M156

TMS Targeting................W103

Tobacco................M238, M255, W259

Tobacco Smoking................M236, M257, T56, T151, T226, W245

Tolcapone................M212, W152, W157

Tolerability................M150

Tonic Inhibition................48

Top-Down Control................M141, T170

Toxicology................W175

Trace Amine-Associated Receptor 1................36.1, 36.2, T173, T243

Trace Amines................36, 36.3, 36.4

Tract Tracing................13.1

Tractography................6.3

Training................W189

Trajectories................M230

Transcranial Direct Current Stimulation (tDCS)................17, 17.1, 17.2, 41.1

Transcranial Magnetic Stimulation (TMS)................21.1, M32, M186, M222, T28, W103

Transcript Isoforms................20

Transcription Factors................49.3

Transcriptome................50.2, M104, T26, T56

Transcriptome Biology................50.4

Transcriptomics................M26, T35, T148

Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)................W15, W89

Transdiagnostic................61

Transdifferentiation................49.3, T188

Transgenerational................57, 57.3, 57.4, M137

Translational Neuroscience................28, 37, 60, M23, M95

Trans-Synaptic Bridges................22.2

Trauma................W8

Trauma And Stress Disorders................M56

Trauma Exposure................M262

Traumatic Brain Injury................24, 46, 46.4, W49, W152, W157

Traumatic Stress................M11, M18

Treatment................M218, T53, T132, T215, T253, W29, W77

Treatment Adherence................T189

Treatment Outcome................6.4, 41.2, M93, T182

Treatment Outcome Prediction................M55

Treatment Resistance................W101

Treatment Resistant Depression................6, 6.2, 6.3, M56, M66, M80, M93, M96, M115, T28, T33, T113, T122, W74, W119

Treatment Response................W180, W216

Treatment Target................s41

Treatment-Resistant Schizophrenia................T194, T210

Trichotillomania................T104

Triple-Deuterated L-Dopa................M154

TrkB................M223, T83

TSPO................58.4, M77, W155

TSPO and [11C]PBR-28 PET................M83

TSPO VT................T74

Twins................T206

Two-Photon................43.1

Type-2 Diabetes................T211, W4

U

Ubiquitination................W176

Unaffected Relatives................W184

Unpredictable Stress................T223

V

Vagus Nerve Stimulation................M263

Valence................M9, T2

Varenicline................M268, W261

Vasopressin................T87

VEGF-R2................M148

Ventral Attention................T44

Ventral Hippocampus................M15, T110, W70

Ventral Pallidum................T50, W263

Ventral Striatum................M169, M240, W18

Ventral Tegmental Area (VTA)................9.2, 15.3, M211, M220, T61, T174, W131, W257, W263

Ventrolateral Striatum................T157

Ventromedial................3.3

Verbal Episodic Memory................T94

Veterans................W84

Vilazodone................M126

Violence................T11, T81

Visual Contrast Sensitivity................W217

Visual Cortex................T170

Visual Information Processing................W217

Visual Perception................W199

Visuospatial Working Memory................M203

Vitamin E................M147

VLDLR................55.2

vmPFC................11.4, W16

Voltage-Gated Calcium Channel................W90

Voltammetry................24.2, T58, T105

Voxel-Based Morphometry (VBM)................T57, T242, W204

Vulnerability................T206

W

Wakefulness................M220

Weight Gain................M29

Weight Loss................W137

White Matter................M110, M215, W42, W59

Whole Exome Sequencing................T159, T164

Whole Genome Sequencing................23.3, 40

Withdrawal................M252, T151, T220, T247, W267

Within-Pair Concordance................T206

Wnt Signaling................5, M156

Women's Mental Health................W63, W88

Word List Recall Test................T94

Working Memory................24.1, 29.1, T45, T76, T92, T191, T207, T250, W107, W167

X

Xct................43.4

Y

Young Adults................29.2, M239, W267

Youth................34.2, M34

Z

Zebrafish................M23

Zinc-Fingers................15.4

B-Arrestin................M187

Γ Oscillation................T209

ΔFosB................T110